Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 6/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449258 | 0.93 | ABL1 (0.39) | ABL1BCRTHRBEGFRCSNK2A1 | |
| SCHEMBL3463873 | 0.90 | EGFR (0.39) | ABL1BCRTHRBEGFRCSNK2A1 | |
| SCHEMBL3449032 | 0.90 | XDH (0.40) | THRBEGFRCSNK2A1L3MBTL1STK17A | |
| SCHEMBL3447262 | 0.88 | RXFP1 (0.40) | ABL1BCRTHRBEGFRCSNK2A1 | |
| SCHEMBL3450187 | 0.85 | CSNK2A1 (0.40) | ABL1BCRTHRBEGFRCSNK2A1 | |
| SCHEMBL3447526 | 0.84 | ABL1 (0.43) | ABL1BCREGFRCSNK2A1SYK | |
| SCHEMBL3448814 | 0.84 | EGFR (0.39) | ABL1BCRTHRBEGFRSYK | |
| SCHEMBL3450030 | 0.84 | ABL1 (0.38) | ABL1BCREGFRCSNK2A1SYK | |
| SCHEMBL3451486 | 0.83 | THRB (0.43) | ABL1BCRTHRBEGFRCSNK2A1 | |
| SCHEMBL3450614 | 0.82 | ABL1 (0.41) | ABL1BCREGFRCSNK2A1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | ABL1 370/4885BCR 3224/4885THRB 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.